AGIO
Agios Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$33.10
−0.09%Year over year
Reported trailing growth
- Revenue
- +140.6%
- EBITDA
- +1.7%
- EBIT
- +0.5%
- EPS
- —
- Free cash flow
- +10.7%
- Operating cash flow
- +11.2%
Forward estimates
Based on analyst estimates
- Revenue
- +173.1%
- EBITDA
- +41.1%
- EPS
- +39.3%
Three-year CAGR
- Revenue
- +56.0%
- EBITDA
- —
- EBIT
- -10.9%
- Net income
- —
- EPS
- —
- Free cash flow
- +3.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026